Patients with a history of congestive heart failure (CHF) or are at risk because of underlying cardiovascular disease or exposure to cardiotoxic drugs must have adequate cardiac function as clinically indicated:\r\n* Corrected QT interval (QTC) =< 480 msec\r\n* Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by echocardiogram or radionuclide angiogram
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or
Patient must have a normal cardiac ejection fraction by pretreatment multigated acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration (resting ejection fraction >= 40% or >= 5% increase with exercise), shortening fraction by echocardiogram >= 24%, or to within the normal range of values for the institution
Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by radionuclide angiogram
Shortening fraction >= 27% by echocardiogram, or ejection fraction >= 50% by gated radionuclide study \r\n* Patients must have an electrocardiogram (EKG) fewer than 6 days prior to enrollment on the dasatinib arm; patients who have had cardiac assessments by echocardiogram or radionuclide scan at the beginning of induction do not need to have these repeated prior to study entry; correct QT interval (QTc) < 450 msec on baseline electrocardiogram as measured by the Frederica or Bazett formula\r\n* No major conduction abnormality (unless a cardiac pacemaker is present)
Shortening fraction of >= 27% by echocardiogram, or
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
Shortening fraction of >= 27% by echocardiogram, or
Shortening fraction of >= 27% by echocardiogram
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
Shortening fraction of >= 27% by echocardiogram (for patients on doxorubicin-containing regimens [Groups C, D, E, and F]), or
Adequate Cardiac Function defined as: Shortening fraction of ? 27% by echocardiogram, or Ejection fraction of ? 50% by radionuclide evaluation or echocardiogram.
Shortening fraction of >= 27% by echocardiogram (while not receiving medications for cardiac function), or
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Patients must have adequate cardiac function as defined as:\r\n* Shortening fraction of ? 27% by echocardiogram, or\r\n* Ejection fraction of ? 50% by radionuclide angiogram
Shortening fraction > 28% by echocardiogram or Ejection Fraction of > 50 % by multigated acquisition (MUGA)
Within 4 weeks prior to study enrollment: Shortening fraction of >= 27% by echocardiogram OR
Shortening fraction >= 28% by echocardiogram OR ejection fraction of >= 50 % by multigated acquisition (MUGA)
Shortening fraction of >= 27% by echocardiogram, OR
Ejection fraction of >= 50% by gated radionuclide study/echocardiogram
Shortening fraction >= 28% by echocardiogram or ejection fraction of >= 50 % by multigated acquisition (MUGA)
Shortening fraction of >= 27% by echocardiogram OR
Shortening fraction > 28% by echocardiogram or ejection fraction of > 50 % by MUGA
Shortening fraction > 28% by echocardiogram or
Ejection fraction > 50% by echocardiogram or radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study within 7 days prior to enrollment
Echocardiogram must have a shortening fraction or an ejection fraction greater than institutional lower limit of normal for age and gender; echocardiogram must be obtained while patient is not receiving cardiotropic medications (eg., pressors or afterload reducers)
Adequate cardiac function defined as: normal 12 lead electrocardiogram (EKG) with corrected QT interval (QTc) < 450 msec, and either shortening fraction of >= 28% by echocardiogram and qualitatively normal left ventricular function, or ejection fraction of >= 55% by echocardiogram
Patient must have normal cardiac function documented by ejection fraction (> 55%) documented by echocardiogram or radionuclide MUGA evaluation or fractional shortening ( > 27%) documented by echocardiogram and EKG must demonstrate no abnormality severe enough to justify cardiac medications and baseline QTc interval less than or equal to 450 msecs
Ejection fraction >= 45% on echocardiogram
Shortening fraction of >= 27% by echocardiogram, or ejection fraction (left ventricular ejection fraction [LVEF]) >= 50% by gated radionuclide study
Shortening fraction > 24% by echocardiogram, or ejection fraction > 30% by radionuclide angiogram
Shortening fraction of >= 27% by echocardiogram
Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide MUGA evaluation OR normal fractional shortening (>= 27%) documented by echocardiogram
Shortening fraction of >= 27% by echocardiogram, or
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
Shortening fraction >= 28% by echocardiogram or ejection fraction >= 50% by echocardiogram or radionuclide study
Shortening fraction of >= 27% by echocardiogram, or
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram
Shortening fraction >= 27% by echocardiogram, or
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
For patients on Part B: shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study
Shortening fraction of >= 27% by echocardiogram (ECHO) OR
Shortening fraction >= 27% by echocardiogram
Ejection fraction > 50% on echocardiogram
Ejection fraction >= 50% by echocardiogram
Shortening fraction >= 28% on screening echocardiogram
Shortening fraction greater than or equal to 28% by echocardiogram OR
Patients must have a shortening fraction greater than or equal to 27% by echocardiogram, OR ejection fraction greater than or equal to 50% by radionuclide angiogram (multigated acquisition [MUGA])
Adequate cardiac function defined as shortening fraction of ? 27% by echocardiogram or ejection fraction ? 45% by gated radionuclide study.
Ejection fraction >= 50% by echocardiogram
NON-PROGRESSED DIPG (STRATUM 2): Left ventricular ejection fraction >= 50 by gated radionuclide study OR shortening fraction of >= 27% by echocardiogram
Shortening fraction of >= 27% by echocardiogram, or
Cardiac Function: Patient must have a shortening fraction (SF) of > 27% or an ejection fraction (EF) of > 50% by echocardiogram or MUGA scan.
Shortening fraction of >= 27% by echocardiogram
Shortening fraction greater than or equal to 28% by echocardiogram OR
Shortening fraction of >= 27% by echocardiogram or ejection fraction >= 45% by gated radionuclide study
Shortening fraction >= 27% by echocardiogram or
Shortening fraction of >= 25% by echocardiogram
Must have electrocardiogram (EKG) with corrected QT (QTc) interval < 450 msec and Echocardiogram with shortening fraction >= 27% or ejection fraction > 50%
Shortening fraction greater than or equal to 27% by echocardiogram; corrected QT interval =< 450 milliseconds
Shortening fraction of >= 27% by echocardiogram, or if shortening fraction abnormal, ejection fraction of >= 55% by gated radionuclide study or echocardiogram; note: the echocardiogram or gated radionuclide study must be performed within 4 weeks prior to enrollment
Shortening fraction on echocardiogram > 28%
Ejection fraction of < 50% (by radionuclide angiogram or echocardiogram) or shortening fraction of < 25% (by echocardiogram)\r\n* Note: for instances where both are reported, and one is below the threshold, the site will have the option to re-measure it centrally at the core lab
Cardiac function: Ejection fraction at rest ? 45.0% or shortening fraction of ? 27.0% by echocardiogram or radionuclide scan (MUGA).
Shortening fraction > 27% by echocardiogram, or
Ejection fraction of > 47% by radionucleotide angiogram or echocardiogram
Shortening fraction of > 25% by echocardiogram, or
Ejection fraction of > 40% by radionuclide angiogram or echocardiogram
